SCHEMBL17358752

SCHEMBL17358752

CC(C)(C)OC(=O)[C@H]1CC(=O)CCN1C(=O)OC(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.41
NPC1 O15118 1/20 0.39
UCHL1 P09936 2/20 0.39
NR1H2 P55055 2/20 0.38
MAPK1 P28482 1/20 0.38
EPHX2 P34913 1/20 0.38
LMNA P02545 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
NR1H3 Q13133 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
PTPN1 P18031 1/20 0.36
ESR2 Q92731 1/20 0.36
USP2 O75604 1/20 0.36
SCN4A P35499 1/20 0.35
USP30 Q70CQ3 1/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
GLA P06280 1/20 0.35
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30289230 1.00 HSD17B10 (0.41) HSD17B10NPC1UCHL1NR1H2MAPK1
SCHEMBL8235326 1.00 HSD17B10 (0.41) HSD17B10NPC1UCHL1NR1H2MAPK1
SCHEMBL10269872 0.91 NR1H2 (0.45) HSD17B10NPC1UCHL1NR1H2EPHX2
SCHEMBL18084470 0.91 NR1H2 (0.45) HSD17B10NPC1UCHL1NR1H2EPHX2
SCHEMBL4864314 0.91 NR1H2 (0.45) HSD17B10NPC1UCHL1NR1H2EPHX2
SCHEMBL16168073 0.90 NR1H2 (0.39) HSD17B10NPC1UCHL1NR1H2EPHX2
SCHEMBL4631990 0.90 HSD17B10 (0.39) HSD17B10NPC1UCHL1NR1H2EPHX2
SCHEMBL4547486 0.88 HSD17B10 (0.47) HSD17B10NPC1UCHL1NR1H2LMNA
SCHEMBL4869226 0.88 HSD17B10 (0.47) HSD17B10NPC1UCHL1NR1H2LMNA
SCHEMBL10215478 0.88 NPC1 (0.41) HSD17B10NPC1UCHL1NR1H2EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2864318-B1 2-AMINOPYRAZINE DERIVATIVES AS CSF-1R KINASE INHIBITORS MACROPHAGE PHARMA LTD (GB) 2017-08-09 EP disclosed
US-20170157118-A1 2-AMINOPYRAZINE DERIVATIVES AS CSF-1 R KINASE INHIBITORS MACROPHAGE PHARMA LIMITED (GB) 2017-06-08 US disclosed
US-20170157118-A1 2-AMINOPYRAZINE DERIVATIVES AS CSF-1 R KINASE INHIBITORS MACROPHAGE PHARMA LIMITED (GB) 2017-06-08 US disclosed
US-9604940-B2 2-aminopyrazine derivatives as CSF-1R kinase inhibitors CHROMA THERAPEUTICS LTD. (GB) 2017-03-28 US disclosed
US-9604940-B2 2-aminopyrazine derivatives as CSF-1R kinase inhibitors CHROMA THERAPEUTICS LTD. (GB) 2017-03-28 US disclosed
US-20150368210-A1 2-AMINOPYRAZINE DERIVATIVES AS CSF-1 R KINASE INHIBITORS CHROMA THERAPEUTICS LTD. (GB) 2015-12-24 US disclosed
US-20150368210-A1 2-AMINOPYRAZINE DERIVATIVES AS CSF-1 R KINASE INHIBITORS CHROMA THERAPEUTICS LTD. (GB) 2015-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170157118-A1 2-AMINOPYRAZINE DERIVATIVES AS CSF-1 R KINASE INHIBITORS CSF1R, CSF3R, FLT3 HSD17B10 4299/4885NPC1 2932/4885UCHL1 3790/4885
US-20150368210-A1 2-AMINOPYRAZINE DERIVATIVES AS CSF-1 R KINASE INHIBITORS CSF1R, CSF3R, FLT3 HSD17B10 4299/4885NPC1 2932/4885UCHL1 3790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.